T-DXd is currently revolutionizing the treatment of the HER2 molecular sub-class in breast carcinoma and is also the only FDA-approved targeted therapy for NSCLC patients with HER2 mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.